A TERT mutation is a change in the gene that encodes telomerase reverse transcriptase, the enzyme responsible for rebuilding the protective caps on the ends of your chromosomes. In healthy adult cells, TERT is mostly switched off, which is why cells can only divide a limited number of times before their chromosome tips wear down too far. When mutations flip TERT back on in cells that should have it silenced, those cells gain the ability to keep dividing indefinitely, and that is one of the core steps in how many cancers develop. But TERT mutations are not exclusively a cancer story. Inherited versions can cause serious lung, liver, and blood disorders, and the enzyme itself turns out to have roles in the body that go well beyond chromosome maintenance.
What TERT Normally Does
Every time a cell divides, the protective stretches of DNA at the ends of its chromosomes, called telomeres, get a little shorter. Once they shrink past a critical length, the cell receives a signal to stop dividing or to self-destruct. This built-in countdown acts as a brake on uncontrolled growth. TERT is the catalytic core of telomerase, the enzyme that can add DNA back onto those shrinking ends. In most of your body’s cells after early development, the TERT gene is tightly shut down, so telomerase stays inactive and the countdown proceeds as expected. The exceptions are stem cells, immune cells that need to multiply rapidly, and a handful of other highly active cell populations where telomerase remains on to support ongoing renewal.1PubMed Central. Telomerase Reverse Transcriptase (TERT) in Action: Cross-Talking with Epigenetics
This arrangement works well under normal conditions. Cells that need to proliferate a lot keep their telomeres topped up. Cells that do not are slowly retired. The problem begins when something goes wrong with the TERT gene itself, either turning it on when it should be off or crippling it in cells that need it.
Promoter Mutations and How They Hijack the Gene
The most studied TERT mutations in cancer are not changes in the protein-coding part of the gene. They sit in the promoter, the stretch of DNA just upstream that controls whether the gene gets read at all. Two specific spots, often labeled C228T and C250T, account for the vast majority of these promoter mutations. What they do is create a new binding site for a family of proteins called ETS transcription factors, which then latch on and crank up TERT production in cells that would normally keep the gene silent.2Cancer Letters. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends
The practical consequence is stark. In experiments using human embryonic stem cells engineered to carry the most common promoter mutation (C228T), TERT expression jumped roughly two- to threefold compared to cells with a normal promoter. More critically, when those stem cells were coaxed into becoming ordinary body cells, the ones with the mutation never properly shut TERT down. Within days, the mutant cells were producing several times more TERT than their normal counterparts, and that gap widened over time.3PubMed Central. Cancer-associated TERT promoter mutations abrogate telomerase silencing The result is a cell that never hits the normal limit on division. It has gained what researchers call replicative immortality, and that is one of the foundational traits a cell needs to become cancerous.4PubMed Central. Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters
Importantly, TERT promoter mutations alone do not produce a full-blown tumor. They remove one barrier to unlimited growth, but a cancer cell typically accumulates several other mutations in different pathways. Still, the fact that these promoter changes are sufficient on their own to override telomere-based growth limits makes them an unusually powerful single step on the path to malignancy.5eLife. Cancer-associated TERT promoter mutations abrogate telomerase silencing
Which Cancers Carry TERT Promoter Mutations Most Often
TERT promoter mutations are not spread evenly across cancer types. They cluster heavily in a handful of tumor categories. A large cross-cancer analysis found these mutations in about 56% of bladder cancers, 43% of melanomas, 39% of gliomas (brain tumors), 41% of thyroid cancers, and 23% of head and neck cancers.6PubMed Central. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type An earlier multicenter study reported broadly similar numbers, with central nervous system tumors at about 43%, bladder cancer at 59%, and melanoma at 29%.7PubMed. Frequency of TERT promoter mutations in human cancers The small differences between studies reflect differences in sample composition, but the overall picture is consistent: bladder, brain, skin, and thyroid cancers are the primary hot spots.
The distribution also varies by sex and ancestry. In melanoma, men carry TERT promoter mutations more often than women. The same male predominance shows up in liver cancer, cancer of unknown primary, and thyroid cancer. Head and neck cancer bucks the pattern, with women showing a higher mutation rate. On the ancestry side, white patients with melanoma harbor these mutations far more frequently than Asian or Black patients, while Asian patients with head and neck cancer carry them more often than white patients.6PubMed Central. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type These disparities have implications for how clinicians prioritize molecular testing in different populations.
TERT Mutations in Specific Cancer Types
Melanoma
In melanoma, TERT promoter mutations frequently coexist with mutations in BRAF or NRAS, two well-known drivers of skin cancer. When both a TERT promoter mutation and a BRAF or NRAS mutation are present in the same tumor, the prognosis worsens considerably. One study of early-stage (stage I and II) melanoma patients found that this combination was associated with a roughly twofold drop in disease-free survival and a fivefold reduction in melanoma-specific survival compared to tumors without the mutations.8PubMed Central. TERT promoter mutations in melanoma survival This makes TERT promoter status a potentially useful marker for identifying patients who look like they have low-risk melanoma on paper but may actually face more aggressive disease.
There is also evidence linking TERT promoter mutations in skin cancer to ultraviolet radiation. In basal cell carcinoma, TERT mutations were more common in tumors arising on sun-exposed skin, and the pattern of mutations bore the signature of UV-induced DNA damage.9PubMed. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation This suggests that cumulative sun damage may directly cause these mutations in some cases, adding TERT promoter changes to the list of ways UV light contributes to skin cancer.
Brain Tumors
Glioblastoma, the most aggressive common brain tumor, has one of the highest rates of TERT promoter mutations of any cancer. In one series, nearly 90% of primary glioblastomas carried the mutation.10PubMed Central. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas The most common molecular profile in glioblastoma is a TERT promoter mutation paired with an absence of IDH mutations, a combination that defines the classic, poor-prognosis subtype.11PubMed Central. TERT Promoter Alterations in Glioblastoma: A Systematic Review Among lower-grade brain tumors, TERT promoter mutations are very common in oligodendrogliomas (roughly 83% in one study) but uncommon in astrocytomas (about 20%).10PubMed Central. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas This pattern is now part of how brain tumors are classified. TERT promoter status, along with IDH mutation status and a chromosomal deletion called 1p/19q co-deletion, helps pathologists sort brain tumors into molecular subtypes that carry different prognoses and may respond to different treatments.
Thyroid Cancer
TERT promoter mutations show up across several thyroid cancer subtypes, but they concentrate in the most aggressive forms. Anaplastic thyroid carcinoma, one of the deadliest cancers of any type, carries TERT promoter mutations in roughly 56% of cases. The diffuse sclerosing variant of papillary thyroid carcinoma shows an even higher rate, around 60%.12PubMed. Exploring the role of TERT in thyroid Cancer: A systematic review In contrast, benign thyroid nodules and medullary thyroid carcinoma (which arises from a different cell type) do not carry these mutations at all. Across the board, TERT promoter mutations in thyroid cancer are tied to advanced stage, the presence of distant metastases, reduced overall survival, higher recurrence rates, and resistance to radioactive iodine therapy.13PubMed Central. TERT promoter mutations in thyroid cancer Much like in melanoma, the combination of a TERT promoter mutation with a BRAF mutation (specifically V600E) is especially worrisome.14PubMed Central. Highly prevalent TERT promoter mutations in aggressive thyroid cancers
Bladder and Liver Cancers
Bladder cancer has the highest overall frequency of TERT promoter mutations of any major cancer type, and this has practical diagnostic value. In liver cancer, these mutations are interesting for a different reason: they appear at surprisingly early stages. In patients with cirrhosis, TERT promoter mutations have been detected in pre-cancerous lesions called dysplastic nodules, including low-grade ones that are not yet frankly malignant.15PubMed. TERT promoter mutations in primary liver tumors This suggests TERT activation may be one of the earliest genetic steps on the road from chronic liver disease to liver cancer.
Inherited TERT Mutations and Telomere Syndromes
Everything discussed so far involves somatic mutations, changes that arise in individual cells during a person’s lifetime. But TERT mutations can also be inherited. These germline mutations do not turn TERT on inappropriately. Instead, they cripple the enzyme, leaving cells unable to maintain their telomeres even in tissues where telomerase should be active. The result is a set of conditions collectively called telomere syndromes or telomeropathies.
The most prominent manifestation is pulmonary fibrosis. Inherited loss-of-function TERT mutations are a major single-gene cause of the disease. One study of multiple families carrying these mutations found that pulmonary fibrosis was age-dependent, not appearing in carriers younger than 40 but developing in about 60% of male carriers over 60. Environmental factors like cigarette smoking accelerated the disease. Once diagnosed, the fibrosis was progressive and typically fatal, with an average survival of about three years.16PLOS ONE. Telomere lengths, pulmonary fibrosis and telomerase (TERT) Mutations
Beyond the lungs, germline TERT mutations are associated with liver abnormalities, skin changes, and bone marrow failure, a constellation that overlaps with dyskeratosis congenita, a rare inherited condition driven by defective telomere maintenance.17European Respiratory Journal. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis Patients with these mutations also tend to have shorter telomeres throughout their bodies, not just in the affected organ, confirming that the problem is systemic even when symptoms appear in one place.
Beyond Telomeres: TERT’s Other Roles in the Cell
For years, researchers treated TERT as a single-purpose enzyme: it lengthens telomeres, full stop. That picture has changed. TERT turns out to have a second life inside cells, performing tasks that have nothing to do with chromosome ends. It can move into the nucleus and act as a chromatin modulator, influencing which genes get turned on or off. It helps manage the cell’s response to certain types of DNA damage, independent of telomere length. And it appears to protect against cell death following severe DNA breaks.18PubMed. Non-canonical Functions of Telomerase Reverse Transcriptase: Emerging Roles and Biological Relevance
Perhaps most surprising is TERT’s involvement with mitochondria, the cell’s energy-producing structures. TERT can be shuttled into mitochondria, where it binds to mitochondrial DNA and influences mitochondrial replication and dynamics. Experimental work has shown that TERT affects mitochondrial shape and fragmentation, and may play a role in regulating the recycling of damaged mitochondria, a process critical to cellular health.19PLOS Genetics. TERT translocation to mitochondria: Exploring its role in mitochondrial homeostasis These non-telomere functions help explain why TERT mutations, both gain-of-function and loss-of-function, can have consequences that extend well beyond what you’d expect from telomere length changes alone.
The Alternative Pathway and Why Some Cancers Skip TERT Entirely
Not every cancer relies on TERT to maintain its telomeres. About 10 to 15% of tumors use a completely different mechanism called alternative lengthening of telomeres, or ALT, which hijacks the cell’s DNA recombination machinery to copy telomere sequences from one chromosome to another.20PubMed Central. New twists to the ALTernative endings at telomeres ALT and TERT activation produce different genomic signatures. Tumors that use TERT tend to actually lose some overall telomere content compared to surrounding normal tissue, while ALT-active tumors tend to accumulate extra-long, heterogeneous telomeres.21Nature Communications. Genomic footprints of activated telomere maintenance mechanisms in cancer
Brain tumors illustrate this split well. Low-grade oligodendrogliomas overwhelmingly use TERT, while low-grade astrocytomas predominantly use ALT.22Neuro-Oncology. TAMI-08. A TALE OF TWO TELOMERE MAINTENANCE MECHANISMS: TERT EXPRESSION AND THE ALT PATHWAY INDUCE UNIQUE MRS-DETECTABLE METABOLIC REPROGRAMMING IN LOW-GRADE GLIOMAS This distinction matters for treatment because therapies aimed at blocking TERT would be useless against an ALT-driven tumor, and vice versa. Any effective anti-telomere strategy in cancer will eventually have to account for which maintenance route a given tumor has chosen.
Epigenetic Activation Without a Mutation
TERT promoter mutations are the most discussed way cancers reactivate telomerase, but they are not the only way. In a substantial fraction of tumors, the TERT promoter carries no mutation at all, yet telomerase is active anyway. One major explanation is epigenetic: a region of the TERT promoter called THOR (TERT hypermethylated oncological region) can become heavily methylated in cancer cells. When THOR is unmethylated, it acts as a strong repressor, keeping TERT silent. When it picks up methyl groups, that repressive function is lost, and TERT expression rises. Analysis of over 1,300 tumors found THOR hypermethylation in more than 45% of cases across 9 of 11 tumor types examined. Working either independently or together with promoter mutations, THOR hypermethylation helps explain how roughly 90% of human cancers manage to turn on telomerase.23PubMed Central. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer
Separately, some tumors achieve high TERT expression through structural changes: gene amplifications or chromosomal rearrangements that place the TERT gene under the control of a more active regulatory element. These structural variants actually produce larger boosts in TERT expression than the classic point mutations in the promoter do.24PubMed Central. A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing The takeaway is that cancer has multiple routes to the same destination: keeping telomerase running. Promoter mutations are the best-known route, but they are one lane on a multi-lane highway.
Diagnostic and Monitoring Applications
Because TERT promoter mutations are so common in certain cancers and absent in normal tissue, they make attractive targets for non-invasive testing. Bladder cancer surveillance is a leading example. Currently, patients who have been treated for bladder cancer undergo regular cystoscopies, an invasive procedure, to check for recurrence. Urine-based tests that detect TERT promoter mutations in shed tumor DNA offer a less invasive alternative. One study found that testing urinary sediment DNA for TERT mutations detected the mutation in 77% of bladder cancer cases, with an overall accuracy of 84%, which outperformed standard urine cytology.25PubMed. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer
In thyroid cancer, testing a biopsy for TERT promoter mutations can help separate low-risk nodules from potentially aggressive ones, since the mutation is essentially absent in benign thyroid tissue. In brain tumors, TERT status is now part of the standard molecular workup that determines diagnosis and guides treatment planning. As liquid biopsy technologies mature, testing for TERT promoter mutations in blood samples could eventually extend to monitoring treatment response and detecting early recurrence across multiple cancer types.
Therapeutic Targeting of TERT
Given that telomerase is active in most cancers and silent in most healthy cells, it has long seemed like an ideal drug target. In practice, developing effective telomerase inhibitors has proven difficult. No telomerase-directed therapy has received clinical approval to date.26PubMed Central. Targeting telomerase for cancer therapy One reason is that telomerase inhibition does not kill cancer cells quickly. Telomeres erode gradually, so a tumor might need many rounds of division before its telomeres become critically short, giving the cancer time to develop resistance or switch to ALT.
Researchers are pursuing several strategies, including small-molecule inhibitors that block the enzyme directly, antisense oligonucleotides that prevent TERT from being produced, G-quadruplex stabilizers that lock telomeric DNA into structures telomerase cannot extend, and immunotherapies that train the immune system to attack cells displaying TERT fragments on their surfaces.27PubMed Central. The role of telomere and telomerase in cancer and novel therapeutic target: narrative review A newer angle takes aim at the promoter mutations themselves, trying to block the ETS transcription factors that bind the mutant promoter, which would selectively shut down TERT in tumors carrying the mutation while sparing the small number of normal cells that use telomerase through wild-type promoter activity. This mutation-specific approach is still in early stages but represents one of the more precise strategies on the horizon.
TERT Gene Therapy in Aging Research
If loss-of-function TERT mutations cause premature aging and organ failure, could delivering extra TERT slow normal aging? That question has been tested directly in mice. In one widely cited experiment, mice aged one and two years (roughly equivalent to middle-aged and elderly in human terms) received a single treatment with an adeno-associated virus carrying the mouse TERT gene. The treated animals showed improvements in insulin sensitivity, bone density, neuromuscular coordination, and several molecular markers of aging. They also lived longer than untreated controls. Perhaps most reassuringly, the treated mice did not develop more cancer, suggesting that the cancer-promoting potential of telomerase may be reduced when it is introduced into already-adult organisms rather than being constitutively active from birth.28PubMed Central. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer
Translating this to humans is a different matter entirely. Mice have longer telomeres and more active telomerase to begin with, so the biology does not map neatly. The safety bar for a gene therapy meant for healthy aging adults would be far higher than for a cancer treatment. And the question of whether reactivating telomerase in human tissues might eventually seed cancers over decades, something a mouse lifespan cannot test, remains unanswered. Still, these experiments underscore how the same gene can be both a cancer villain and a potential anti-aging tool depending on the context, the timing, and which direction the mutation pushes expression.